Cytotoxic drug sensitivity of epstein-barr virus transformed lymphoblastoid b-cells

Markasz, L. and Stuber, G. and Flaberg, E. and Jernberg, A. G. and Eksborg, S. and Oláh, Éva (2007) Cytotoxic drug sensitivity of epstein-barr virus transformed lymphoblastoid b-cells. BLOOD REVIEWS, 21 (Supl 1). S98-S99. ISSN 0268-960X

Text 1242595.pdf Restricted to Registered users only Download (61kB) | Request a copy

Abstract

Epstein-Barr virus (EBV) is the causative agent of immunosuppression associated lymphoproliferations such as post-transplant lymphoproliferative disorder (PTLD), AIDS related immunoblastic lymphomas (ARL) and immunoblastic lymphomas in X-linked lymphoproliferative syndrome (XLP). The reported overall mortality for PTLD often exceeds 50%. Reducing the immunosuppression in recipients of solid organ transplants (SOT) or using highly active antiretroviral therapy in AIDS patients leads to complete remission in 23 50% of the PTLD/ARL cases but will not suffice for recipients of bone marrow grafts. An additional therapeutic alternative is the treatment with anti-CD20 antibodies (Rituximab) or EBV-specific cytotoxic T-cells. Chemotherapy is used for the non-responding cases only as the second or third line of treatment. The most frequently used chemotherapy regimens originate from the non-Hodgkin lymphoma protocols and there are no cytotoxic drugs that have been specifically selected against EBV induced lymphoproliferative disorders.

Actions (login required)

Edit Item